PharmaCyte Biotech PMCB Stock
PharmaCyte Biotech Price Chart
PharmaCyte Biotech PMCB Financial and Trading Overview
| PharmaCyte Biotech stock price | 0.93 USD |
| Previous Close | 3.05 USD |
| Open | 3.04 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 2.99 - 3.04 USD |
| 52 Week Range | 1.99 - 3.23 USD |
| Volume | 37.91K USD |
| Avg. Volume | 68.33K USD |
| Market Cap | 50.89M USD |
| Beta (5Y Monthly) | -0.030985 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0.06 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PMCB Valuation Measures
| Enterprise Value | -19437894 USD |
| Trailing P/E | N/A |
| Forward P/E | -7.9736843 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.7154663 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
PharmaCyte Biotech Stock Price History
| Beta (5Y Monthly) | -0.030985 |
| 52-Week Change | 41.58% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.23 USD |
| 52 Week Low | 1.99 USD |
| 50-Day Moving Average | 3.02 USD |
| 200-Day Moving Average | 2.89 USD |
PMCB Share Statistics
| Avg. Volume (3 month) | 68.33K USD |
| Avg. Daily Volume (10-Days) | 45.24K USD |
| Shares Outstanding | 16.79M |
| Float | 12.48M |
| Short Ratio | 0.59 |
| % Held by Insiders | 15.06% |
| % Held by Institutions | 27.01% |
| Shares Short | 45.87K |
| Short % of Float | 0.29% |
| Short % of Shares Outstanding | 0.27% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:1550 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | April 30, 2022 |
| Most Recent Quarter (mrq) | January 31, 2023 |
| Next Fiscal Year End | April 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -5.19% |
| Return on Equity (ttm) | -6.66% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -5612362 USD |
| Diluted EPS (ttm) | -0.26 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 72.64M USD |
| Total Cash Per Share (mrq) | 4.16 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 87.966 |
| Book Value Per Share (mrq) | 4.235 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -4697183 USD |
| Levered Free Cash Flow (ttm) | -3548070 USD |
Profile of PharmaCyte Biotech
| Country | United States |
| State | NV |
| City | Las Vegas |
| Address | 3960 Howard Hughes Parkway |
| ZIP | 89169 |
| Phone | 917 595 2850 |
| Website | https://pharmacyte.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4 |
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Q&A For PharmaCyte Biotech Stock
What is a current PMCB stock price?
PharmaCyte Biotech PMCB stock price today per share is 0.93 USD.
How to purchase PharmaCyte Biotech stock?
You can buy PMCB shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for PharmaCyte Biotech?
The stock symbol or ticker of PharmaCyte Biotech is PMCB.
Which industry does the PharmaCyte Biotech company belong to?
The PharmaCyte Biotech industry is Biotechnology.
How many shares does PharmaCyte Biotech have in circulation?
The max supply of PharmaCyte Biotech shares is 6.8M.
What is PharmaCyte Biotech Price to Earnings Ratio (PE Ratio)?
PharmaCyte Biotech PE Ratio is 15.50000000 now.
What was PharmaCyte Biotech earnings per share over the trailing 12 months (TTM)?
PharmaCyte Biotech EPS is 0.06 USD over the trailing 12 months.
Which sector does the PharmaCyte Biotech company belong to?
The PharmaCyte Biotech sector is Healthcare.
PharmaCyte Biotech PMCB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
- {{ link.label }} {{link}}